Evaluation of diabetic marker Hba1c and anemia in the context of kidney disease
نویسنده :
تاریخ انتشار : 1396/05/23
Each year, more than 100,000 people in the United States are diagnosed
with kidney failure, the fi nal stage of kidney disease.1
The most common cause is diabetes, accounting for nearly 44
percent of new cases.1 Often, a consequence of kidney disease is
anemia. This occurs when kidneys fail to generate enough erythropoietin
hormone to trigger adequate red blood cell production.
For decades, clinicians have successfully used the hemoglobin A1c
(HbA1c or A1C) assay to monitor long-term blood glucose control
for patients with chronic diabetes.2,3 More recently, researchers
have studied the HbA1c assay’s use as a potential diagnostic
marker for diabetes complications such as kidney disease